Key points

  • Alexandria Venture Investments, LLC bought $2.50 million of TRex Bio, Inc. stock on October 13th, 2026. The purchase covered 178,571 shares and arrived in a single Form 4 filing.
  • Every share was reported at $14.00. The price range on the filing opens and closes at the same number, which points to one block rather than a series of open market fills.
  • The buyer is an institution, not an individual. Alexandria Venture Investments, LLC is listed in the filing under the role of Other, the category used for reporting persons who are neither officers nor directors.
  • TRXB last traded at $14.16 against a market capitalization of $388,630,848. That puts the transaction price modestly below the most recent quote.

TRex Bio, Inc. (TRXB) drew a $2.50 million purchase from Alexandria Venture Investments, LLC on October 13th, 2026. The firm acquired 178,571 shares, all of them reported at $14.00.

The buy came through one filing. TRex Bio operates in biological products, excluding diagnostic substances, and carries a market capitalization of $388,630,848. The last price on the stock is $14.16.

What the filing shows

The Form 4 covers a single transaction date, October 13th, 2026, and a single price. When the low and the high of a reported range are both $14.00, the trade is usually a negotiated block or a subscription at a set price rather than accumulation across a session. Nothing in the filing describes the context beyond the figures themselves, and this article does not assume one.

The share count, 178,571, is the kind of number that falls out of dividing a round dollar commitment by a fixed price. The reported dollar value is $2,499,994, which is $2.50 million in round terms. The role field reads Other, which is how a reporting entity that holds a position through ownership or an agreement rather than through a board seat or an executive title is logged.

What the buyer is

Alexandria Venture Investments, LLC is an entity, so none of the usual signals attached to an individual insider apply here. There is no salary to weigh the purchase against, no vesting schedule, no history of personal trading patterns to read. The firm is an institution and the filing treats it as one.

That changes what the data point is worth. An officer buying stock is making a choice with personal money against personal compensation. An institutional holder filing a Form 4 is reporting a position change that falls under Section 16 because of the size or structure of its stake. Both are disclosures. They are not the same disclosure.

What the price says

The purchase price of $14.00 sits below the last traded price of $14.16. That gap is narrow. On a company valued at $388,630,848, a $2.50 million commitment is a position change rather than a controlling move, and readers should size it that way before reading anything further into it.

Biological products companies outside the diagnostics category tend to move on clinical and regulatory calendars rather than on quarterly revenue. That makes any single trading day a poor guide to what a holder with a multi year horizon is doing. The chart above is context for the price, not an explanation of the purchase.

What that leaves

The record here is one filing, one date, one price, and one buyer. There is no cluster of insiders to point to, no pattern across weeks, and no second entity filing alongside. A reader who wants a trend from this data will not find one, because one filing is not a trend.

What is checkable is this: on October 13th, 2026, Alexandria Venture Investments, LLC took 178,571 shares of TRex Bio, Inc. at $14.00 each for $2.50 million, and the stock has since been quoted at $14.16. Anything beyond those figures, including the reason for the purchase, is not in the filing and is not stated here.

The next thing to watch is whether the position is added to or disclosed again. A single institutional Form 4 at a fixed price can be the start of a staged commitment or the whole of it. The filings will say which.

Sources: SEC Form 4 filings retrieved via EDGAR and reviewed by InsiderBuying.com, covering the transaction date of October 13th, 2026.

Informational only, not investment advice.